Sign in
Taking people in FrancePhase 2

Split daily doses of hydroxycarbamide tablets for children with sickle cell disease

Tests split-dose hydroxycarbamide in children with sickle cell disease.

Key facts

Who runs it
Theravia
Where
Cayenne, Creteil Cedex, Le Kremlin-Bicêtre, Meaux, Paris Cedex 15, and St Denis Cedex, FranceSee the 6 sites
Registry title
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Disease: a single-group, non-randomised, open-label study (KID-BID)
Status
Recruiting
Phase
Phase 2
People taking part
50 people, planned
Started
25 Mar 2026
Expected to end
28 Feb 2028
Type of study
Interventional
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with sickle cell disease (HbSS or HbSβ0 type) who have never taken hydroxycarbamide. It tests a twice daily dose of dispersible tablets.

Age
9 months to 11 years
Sex
Boys and girls can both join.
Disease stage
Sickle cell disease of the HbSS or HbSβ0 type. For children over 18 months, a transcranial Doppler scan in the last 12 months must show low risk for stroke.
Earlier treatment
Must never have had hydroxycarbamide (HC), now or before. Must not have had regular blood transfusions or any transfusion in the last 3 months. Must not take other sickle cell disease treatments.
Biomarker or test result
Blood counts: Absolute Neutrophil Count ≥ 1,0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) > 5,5 g/dL.

Main reasons for not taking part

  • Another drug study in the last 4 weeks
  • Chronic kidney disease stage 3, 4 or 5
  • Known HIV, hepatitis B or hepatitis C infection
  • Past stroke or bleeding inside the skull, or an unexplained nerve problem in the last 12 months
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, and, if possible, assent from the children
  • HbSS or HbSβ0 SCD
  • Aged between 9 months and 11 years old
  • HC-naïve (absence of previous or current treatment with HC)
  • Parent(s) or legally acceptable representative(s) capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements
  • Contraception criterion, if applicable: for patients who are sexually active Female patients of childbearing potential (post menarche) at screening agreeing to use a highly effective form of contraception (oral, injected or implanted hormonal contraception, intrauterine device, o abstinence) during the trial and for 3 months after HC discontinuation. Male patients with partners of childbearing potential agreeing to use a highly effective contraception during the trial and for 3 months after HC discontinuation. Male patients with pregnant or lactating partners should be advised to use a barrier method of contraception (condom) to prevent the foetus or breastfed infant from exposure to HC
  • Affiliated to a social security plan (including universal health coverage) or beneficiary of a similar insurance plan
  • Patient must meet the following laboratory values : Absolute Neutrophil Count ≥ 1,0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) > 5,5 g/dL
  • Transcranial Doppler (TCD) in the last 12 months indicating low risk for stroke is required for children over 18 months of age

Who cannot take part

  • Patients treated with other SCD-modifying therapies
  • Patient with a stage 3, 4 or 5 chronic kidney disease (estimated glomerular filtration rate < 60 mL/min per 1.73 m2
  • Patients known to be infected with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus
  • Known hypersensitivity or allergy to the excipients
  • Any surgical or medical condition or any significant illness (of which severe hepatic impairment [Child-Pugh classification C], severe renal impairment, toxic ranges of myelosuppression) that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study
  • Any documented history of a clinical stroke or intracranial haemorrhage, or an uninvestigated neurologic finding within the past 12 months
  • Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding the inclusion visit
  • Patients who have had chronic blood transfusion or transfusion in the last 3 months preceding the inclusion visit
  • Female patients who are pregnant or lactating

Where in France

  • Centre Hospitalier De CayenneCayenne, FranceTaking people
  • Centre Hospitalier Intercommunal CreteilCreteil Cedex, FranceTaking people
  • Hôpital Bicêtre APHPLe Kremlin-Bicêtre, FranceTaking people
  • Grand Hopital de l'Est FrancilienMeaux, FranceTaking people
  • CEREDIH Groupe Hospitalier Necker-Enfants MaladesParis Cedex 15, FranceTaking people
  • Centre Hospitalier General De St DenisSt Denis Cedex, FranceTaking people

About the trial

What the trial wants to find out

The primary objective is to develop a population pharmacokinetic (PPK) model of Siklos® Paediatric dispersible tablets administered BID in children aged 9 months to 11 years.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Disease: a single-group, non-randomised, open-label study (KID-BID)
Plain-language title
Split daily doses of hydroxycarbamide tablets for children with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
24 July 2026